Neurotech International Limited

Equities

NTI

AU000000NTI9

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:40:56 28/05/2024 am IST			5-day change	1st Jan Change
0.073 ^AUD	-1.35%		-2.67%	+5.80%

17/04	Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	MT
17/04	Neurotech International Completes AU$10 Million Capital Raise	MT

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

September 01, 2022 at 11:53 am IST

Neurotech International Limited announced that following recent Board and management changes, Dr. Alexandra Andrews will transition from her current position as Chief Executive Officer (CEO) to a new position of Chief Operating Officer (COO), effective immediately. Alex will continue with the Company in her new capacity of Chief Operating Officer, where she will be providing key scientific, strategic and management input into Neurotech's manufacturing, intellectual property, pre-clinical research and clinical trial development moving forward.

Latest news about Neurotech International Limited

Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	17/04	MT
Neurotech International Completes AU$10 Million Capital Raise	17/04	MT
Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism	10/04	MT
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02	CI
Neurotech Receives Human Research Ethics Committee Approval to Extend Autism Trial	13/02	MT
Neurotech's ASD Drug Trials Exceed 90 Weeks	07/02	MT
Neurotech International Secures Approval to Advance Cerebral Palsy Trial; Shares Rise 6%	29/01	MT
Neurotech International Completes Enrolment for Phase 2/3 Autism Spectrum Trial	19/12	MT
Neurotech International Secures Ethics Approval for Use of Autism Spectrum Medication in Adults	04/12	MT
Neurotech International Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023	14/11	MT
Neurotech International Completes Enrollment for Rett Syndrome Trial	26/23/26	MT
Neurotech International Completes Treatment for Last Patient in Phase I/II PANDAS/PANS Clinical Trial	31/23/31	MT
Neurotech International Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/23/30	CI
Neurotech International Secures Ethics Approval for Clinical Trial of Neurological Medication	10/23/10	MT
Neurotech International Secures Ethics Approval to Extend Use of Medication in Pediatric Trial	30/23/30	MT
Neurotech International Completes Patient Recruitment for Neuropsychiatric Disorder Treatment Trial	03/23/03	MT
Neurotech International Plans to Launch Phase Two Rett Syndrome Trial	20/23/20	MT
Neurotech International Limited Announces the Launch of A New Clinical Program in Rett Syndrome, Commencement of A Phase II Clinical Trial Investigating the Use of NTI164 in Female Patients	20/23/20	CI
Neurotech International Says Considerable Improvement in ASD Patients Treated with NTI164; Shares Decline 9%	17/23/17	MT
Neurotech International Limited Announces the Final Clinical Results from Eleven Paediatric Autism Spectrum Disorder Patients, Following Daily Treatment of NTI164 over 52 Week Period	17/23/17	CI
Neurotech International Halts Trade Pending Release of Clinical Trial Data	15/23/15	MT
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/23/28	CI
Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial	16/23/16	CI
Neurotech International Secures Ethics Approval to Extend Phase 1/2 Autism Trial	14/23/14	MT
Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension	14/23/14	CI

Chart Neurotech International Limited

Duration

Period

More charts

Company Profile

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEUROTECH INTERNATIONAL LIMITED	+5.80%	50.12M
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B

Other Biotechnology & Medical Research